Treatment trials in progressive MS—current challenges and future directions

The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability

(2015) C. H. Polman et al.   NEUROLOGY

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

(2012) Wolfgang Brück et al.   ACTA NEUROPATHOLOGICA

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

(2012) Jack Antel et al.   ACTA NEUROPATHOLOGICA

Cortical lesion load associates with progression of disability in multiple sclerosis

(2012) M. Calabrese et al.   BRAIN

Immune Therapy of Multiple Sclerosis - Future Strategies

(2012) Sven G. Meuth et al.   CURRENT PHARMACEUTICAL DESIGN

From bench to MS bedside: Challenges translating biomarker discovery to clinical practice

(2012) Sathyanath Rajasekharan et al.   JOURNAL OF NEUROIMMUNOLOGY

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

(2012) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Measurement and clinical effect of grey matter pathology in multiple sclerosis

(2012) Jeroen JG Geurts et al.   LANCET NEUROLOGY

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

(2012) D Ontaneda et al.   Multiple Sclerosis Journal

Epigenetic changes in patients with multiple sclerosis

(2012) Marcus W. Koch et al.   Nature Reviews Neurology

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis

(2012) Roberto Madeddu et al.   NEUROLOGICAL SCIENCES

Remyelination Therapy for Multiple Sclerosis

(2012) Michael B. Keough et al.   Neurotherapeutics

Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis

(2012) Marcus W. Koch et al.   TRENDS IN MOLECULAR MEDICINE

Impaired neurosteroid synthesis in multiple sclerosis

(2011) Farshid Noorbakhsh et al.   BRAIN

Fingolimod modulates microglial activation to augment markers of remyelination

(2011) Samuel J Jackson et al.   Journal of Neuroinflammation

Oral treatment for multiple sclerosis

(2011) Joep Killestein et al.   LANCET NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

(2010) Sarah A. Morrow et al.   CLINICAL NEUROPSYCHOLOGIST

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation

(2010) Henrik Wilms et al.   Journal of Neuroinflammation

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?

(2010) LVAE Bosma et al.   Multiple Sclerosis Journal

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis

(2010) Jeremy Chataway et al.   Multiple Sclerosis Journal

Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors

(2009) Mohamed Ouardouz et al.   ANNALS OF NEUROLOGY

Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis

(2009) Laura Garay et al.   BRAIN RESEARCH

Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity

(2009) E M Mowry et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

The search for responsive clinical endpoints in primary progressive multiple sclerosis

(2009) LVAE Bosma et al.   Multiple Sclerosis Journal

The natural history of primary progressive multiple sclerosis

(2009) M. Koch et al.   NEUROLOGY

Remyelination protects axons from demyelination-associated axon degeneration

(2008) K. A. Irvine et al.   BRAIN

Therapeutic Potential of Fluoxetine in Neurological Disorders

(2008) Jop P. Mostert et al.   CNS Neuroscience & Therapeutics

LINGO-1 antagonists as therapy for multiple sclerosis:in vitroandin vivoevidence

(2008) Richard A Rudick et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity

(2008) R.E. Gonsette   JOURNAL OF THE NEUROLOGICAL SCIENCES

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

(2008) D. R. Altmann et al.   NEUROLOGY

MRI as an outcome in multiple sclerosis clinical trials

(2008) M. Daumer et al.   NEUROLOGY